The epidemiological impact of digital and manual contact tracing on the SARS-CoV-2 epidemic in the Netherlands: empirical evidence.

Authors: Wianne Ter Haar^{1,2}, Jizzo Bodriesz^{2,3}, Roderick P. Venekamp¹, Ewoud Schuit¹, Susan van den Hof⁴, Wolfgang Ebbers⁵, Mirjam Kretzschmar^{1,4}, Jan Kluytmans^{1,6}, Carl Moons¹, Maarten Schim van der Loeff^{2,3}, Amy Matser^{2,3}, Janneke H. H. M. van de Wijgert^{1,4*}

* Corresponding author

Affiliations:

- 1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
- 2. Public Health Service (GGD) of Amsterdam, Amsterdam, Netherlands
- 3. Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- 4. National Institute for Public Health and the Environment, Bilthoven, Netherlands
- 5. Department of Public Administration and Sociology, Erasmus University Rotterdam, Rotterdam, Netherlands
- 6. Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

Correspondence:

Janneke van de Wijgert Julius Center for Health Sciences and Primary Care University Medical Center Utrecht Universiteitsweg 100, Stratenum room 7.127, 3584 CG Utrecht Phone: +31 88 75 68356 Email: j.h.h.vandewijgert@umcutrecht.nl

Short title: Impact of SARS-CoV-2 digital contact tracing.

Keywords: SARS-CoV-2, COVID-19, contact tracing, CoronaMelder application, Netherlands

Word counts:

Abstract: 250 Main text: 3,707 References: 32 Number of tables and figures: 4 Supplements: 1

1 Abstract

| 2 | Background. The Dutch government introduced the CoronaMelder smartphone application for digital |
|----|--|
| 3 | contact tracing (DCT) to complement manual contact tracing (MCT) by Public Health Services (PHS) |
| 4 | during the 2020-2022 SARS-CoV-2 epidemic. Modelling studies showed great potential but empirical |
| 5 | evidence of DCT and MCT impact is scarce. |
| 6 | Methods. We determined reasons for testing, and mean exposure-testing intervals by reason for |
| 7 | testing, using routine data from PHS Amsterdam (1 December 2020 to 31 May 2021) and data from |
| 8 | two SARS-CoV-2 rapid diagnostic test accuracy studies at other PHS sites in the Netherlands (14 |
| 9 | December 2020 to 18 June 2021). Throughout the study periods, notification of DCT-identified |
| 10 | contacts was via PHS contact-tracers, and self-testing was not yet widely available. |
| 11 | Results. The most commonly reported reason for testing was having symptoms. In asymptomatic |
| 12 | individuals, it was having been warned by an index case. Only around 2% and 2-5% of all tests took |
| 13 | place after DCT or MCT notification, respectively. About 20-36% of those who had received a DCT or |
| 14 | MCT notification had symptoms at the time of test request. Test positivity after a DCT notification |
| 15 | was significantly lower, and exposure-test intervals after a DCT or MCT notification were longer, than |
| 16 | for the above-mentioned other reasons for testing. |
| 17 | Conclusions. Our data suggest that the impact of DCT and MCT on the SARS-CoV-2 epidemic in the |
| 18 | Netherlands was limited. However, DCT impact might be enlarged if app use coverage is improved, |
| 19 | contact-tracers are eliminated from the digital notification process to minimise delays, and DCT is |

20 combined with self-testing.

21 Author summary

| 22 | During the 2020-2022 SARS-CoV-2 epidemic, the Dutch government introduced digital contact |
|----|---|
| 23 | tracing (DCT) using a smartphone application to complement manual contact tracing (MCT) by |
| 24 | professional contact-tracers. Mathematical models had suggested that DCT could slow down virus |
| 25 | spread by identifying more individuals with whom the smartphone user had been in close contact |
| 26 | and by reducing notification and testing delays after exposure. We used data collected during the |
| 27 | Dutch epidemic to evaluate whether this was indeed the case and found that DCT and MCT had |
| 28 | limited impact. Only around 2% of all tests took place after a DCT notification, and 2-5% after a MCT |
| 29 | notification depending on MCT capacity at the time. Test positivity was lower after a DCT |
| 30 | notification, and exposure-test intervals were longer after a DCT or MCT notification, than for other |
| 31 | reasons for testing. About 20-36% of those who had received a DCT or MCT notification had |
| 32 | symptoms at the time of test request and might have tested anyway even without having received |
| 33 | the notification. However, DCT impact might be enlarged in future epidemics if app use coverage is |
| 34 | improved and all exposure-notification-testing delays are minimised (e.g. no involvement of |
| 35 | professional contact tracers and enabling self-testing after DCT notification). |

36 Introduction

| 37 | Source and contact tracing by public health professionals (manual contact tracing or MCT) is a well- |
|----|--|
| 38 | known method to control the spread of communicable diseases, and was used during the 2020-2022 |
| 39 | SARS-CoV-2 pandemic. However, for the first time, digital contact tracing (DCT) using smartphone |
| 40 | applications was also introduced in many countries worldwide (1–3). These apps differed in their |
| 41 | levels of privacy-by-design, functionalities, and management of detected exposures. But they all had |
| 42 | in common that a notification was triggered if the app user had been exposed to a person who had |
| 43 | tested SARS-CoV-2-positive. In the Netherlands, the app was dubbed CoronaMelder. It was launched |
| 44 | in the 8th month of the Dutch epidemic on 10 October 2020 (see Supplementary introduction for a |
| 45 | detailed history of the Dutch epidemic) (4,5). |
| 46 | |
| 47 | DCT has several theoretical advantages over MCT and over testing because of having symptoms or |
| 48 | having received a warning by an index case. These include identification and notification of more |
| 49 | contacts (including contacts whom the app user does not know personally), reducing delays in |
| 50 | becoming aware of an exposure or presymptomatic infection and getting tested, and increasing |
| 51 | general awareness which might stimulate preventive behaviour (6). Modelling studies from various |
| 52 | countries in the first year of the pandemic suggested that DCT might have a prominent |
| 53 | epidemiological impact, but that the impact depends on user uptake, use coverage, percentage of |
| 54 | exposures detected, testing capacity and policies, and the specifics and delays of the tracing process |
| 55 | (7–10). More empirical evidence is needed to properly quantify these factors for use in future |
| 56 | mathematical transmission models, which are needed to guide policy decisions regarding future |
| 57 | investments in DCT and MCT (1,2). In this paper, we assessed whether DCT and MCT had added value |
| 58 | in SARS-CoV-2 control during the 2020-2021 SARS-CoV-2 epidemic in the Netherlands. We focused |
| 59 | on reasons for testing (including having received an exposure notification via DCT or MCT) and |
| 60 | exposure-test intervals by reason for testing. |

61

62 Materials and Methods

| 63 | In the Netherlands, the general public could get tested at public health service (PHS) test sites (from |
|----|---|
| 64 | 1 June 2020 onwards), commercial test sites (between February 2021 and March 2022), and by self- |
| 65 | testing (from 31 March 2021 onwards). Public testing was free-of-charge for specific indications, and |
| 66 | initially included symptomatic individuals only. Free-of-charge testing of exposed but asymptomatic |
| 67 | individuals with close contacts became possible from 1 December 2020 onwards: the initial |
| 68 | recommendation was to test on the fifth day after exposure, but from 18 February 2021 onwards to |
| 69 | also test as soon as possible after the exposure. Individuals who tested positive at public or |
| 70 | commercial test sites were contacted by a PHS employee and asked about their recent contacts; until |
| 71 | February 2022, individuals with a positive self-test were asked to do a repeat test at a PHS test site to |
| 72 | confirm the result and to enter the PHS MCT programme. During times when the MCT programme |
| 73 | was fully operational, PHS employees notified each reported close contact. However, MCT was |
| 74 | regularly scaled down due to the programme being overwhelmed, and at those times, cases were |
| 75 | asked to notify their close contacts themselves (Supplementary methods). |
| 76 | |
| 77 | The CoronaMelder app was introduced on 10 October 2020 (technical explanations in the |
| 78 | Supplementary introduction and Figure S1). By the end of May 2021, almost 30% of the Dutch |
| 79 | population had downloaded the CoronaMelder app but only around 18% were still actively using it |
| 80 | (5). For DCT to have epidemiological impact, all steps of the exposure-notification-action cascade |
| 81 | should be optimised (Figure 1 and Supplementary introduction): app uptake and active use, detection |
| 82 | of exposures, quarantine and testing once an exposure is detected, and isolation and notification of |
| 83 | contacts after testing positive. App users who tested positive could voluntarily upload that |
| 84 | information (via a so-called PHS-key) from the app to a backend server, which subsequently resulted |

in notifications being sent to all phones with CoronaMelder in active mode that had been within 1.5

- 86 meters for at least 15 minutes within the last 14 days. PHS-keys could initially only be uploaded to
- 87 the backend server after a PHS employee had entered the date of symptom onset or, if no symptoms

- 88 present, the date of the positive test into the PHS-key. From 11 November 2021 onwards (which is
- after the three datasets used in this study had already been collected), app users could upload their
- 90 PHS-key themselves.
- 91
- 92 Figure 1: The exposure-notification-action cascade during the SARS-CoV-2 epidemic in the
- 93 Netherlands, 2020-2021



94

95 See *Supplementary introduction* for detailed explanations of each of these steps.

97 Data sources

| 98 | We could not use data collected via CoronaMelder itself due to the privacy sensitive configuration of |
|-----|---|
| 99 | the app. Instead, we used routinely collected public health data at the PHS Amsterdam and data |
| 100 | from two SARS-CoV-2 rapid diagnostic test (RDT) accuracy studies that were conducted at various |
| 101 | other PHS test sites in the Netherlands. |
| 102 | |
| 103 | PHS Amsterdam data were extracted from the national CoronIT, HPZone, and Osiris databases |
| 104 | (described in the Supplementary methods). We plotted reasons for testing over time for the period 1 |
| 105 | June 2020 (start of public testing for symptomatic individuals) until 31 May 2021, but conducted all |
| 106 | analyses on data collected between 1 December 2020 (DCT available, and DCT and MCT-notified |
| 107 | asymptomatic close contacts could also access public testing) and 31 May 2021. The PHS Amsterdam |
| 108 | dataset contained CoronIT data between 1 December 2020 and 31 May 2021 on age, gender, postal |
| 109 | code, reason for testing, symptoms at the time of test request, date/time of test appointment, |
| 110 | date/time of testing, and test result for 562,159 tests (n_t) by 372,545 individuals (n_i) (Figure S2). |
| 111 | Exposure-testing intervals could only be determined for individuals who had been part of the PHS |
| 112 | Amsterdam MCT programme as either a case or a contact (the PHS Amsterdam MCT subset). CoronIT |
| 113 | data were merged with exposure date data from HPZone (available up to 31 March 2021) and |
| 114 | exposure level data from Osiris. After merging, this PHS Amsterdam MCT subset included 20,647 |
| 115 | exposure-testing intervals (n_{e-t}) by 20,355 individuals (n_i) (Figure S2; merging process described in the |
| 116 | Supplementary methods). |
| 117 | |

The first RDT study was conducted between 14 December 2020 and 6 February 2021 at PHS test sites
in the West-Brabant (Raamsdonksveer and Roosendaal) and the Rotterdam-Rijnmond (Rotterdam
The Hague Airport and Ahoy) regions. The second RDT study took place between 12 April and 18 June
2021 at PHS test sites in the West-Brabant (Breda), Rotterdam-Rijnmond (Rotterdam The Hague
Airport and Ahoy), and IJsselland (Zwolle) regions. The primary diagnostic accuracy results have been

Version 23 March 2023

| 123 | published elsewhere (11,12). Participants provided written informed consent and had to be at least |
|-----|--|
| 124 | 16 years. In the first RDT study, close contacts who were asymptomatic at the time of test request |
| 125 | were eligible for participation, but about 9% of them had developed symptoms by the time of testing |
| 126 | a few days later. The second RDT study included all individuals who scheduled a SARS-CoV-2 test at |
| 127 | the participating PHS sites irrespective of reason for testing. In both studies, participants were asked |
| 128 | to complete short questionnaires developed by the study teams – including questions about reasons |
| 129 | for testing and CoronaMelder use – while waiting to be sampled at the test site (Figure S3). The |
| 130 | questionnaire data were merged with the PHS test data including test results. The first RDT study |
| 131 | dataset contained 4,126 individuals (Figure S4). The second RDT study dataset contained 7,925 |
| 132 | individuals but date of last exposure, and thereby an exposure-testing interval, was only available for |
| 133 | 3,172 individuals (Figure S4). |
| 134 | |
| 135 | Statistical analyses |
| 136 | In all datasets, individuals could report multiple reasons for testing (Table 1 for an overview of these |
| 137 | reasons). Symptoms could have been reported as a reason for testing, but anyone requesting a test |
| 138 | or participating in one of the studies was also asked if they had any symptoms as a standalone |
| 139 | question. These questions were asked at the time of test request in the PHS Amsterdam dataset and |
| 140 | at the time of testing in the two RDT studies. In most analyses (unless noted otherwise below), we |
| 141 | used a hierarchy to limit the number of reasons for testing categories. The hierarchy in the PHS |
| 142 | Amsterdam dataset was DCT notification, MCT notification, having symptoms without notification, |
| 143 | and unknown. The hierarchy in the first and second RDT studies, was DCT notification, MCT |
| 144 | notification, followed by other types of notifications and other types of reasons for testing |
| 145 | (Supplementary methods). We used the last date of exposure/contact, and the date a test sample |
| 146 | was taken, to calculate the exposure-testing interval in all datasets. |
| 147 | |
| | |

148 Reasons for testing over time were displayed graphically. Population characteristics by reason for

Version 23 March 2023

149 testing were tabulated per data source and compared using Pearson's Chi-squared test for 150 categorical variables and Kruskal-Wallis test for continuous variables. Adjusted standardized residuals 151 of statistically significant categorical variables (p<0.05) were subsequently compared to the critical 152 value, with p-values adjusted by the Bonferroni method. Continuous variables that differed 153 statistically significantly between groups were subsequently analysed by Dunn Kruskal-Wallis 154 multiple comparison test, with p-values adjusted by the Benjamini-Hochberg method. Mean 155 exposure-testing intervals with standard deviations (SD) were calculated by reason for testing and by 156 other population characteristics. Univariable and multivariable Weibull regression and tobit censored 157 regression models were performed to estimate associations between characteristics and exposure-158 testing intervals. Reason for testing was included in these models as an indicator variable to allow for 159 reporting of multiple reasons per person. Weibull models were a better fit than tobit models because 160 testing peaked on day five after exposure, especially in the first RDT dataset. However, both types of 161 models were fit, with tobit models considered a sensitivity analysis. In the PHS Amsterdam regression 162 models, all individuals for whom an exposure-testing interval could be determined had been part of 163 the MCT programme, and MCT was therefore not included as a variable. All statistical analyses were 164 performed in R versions 3.6.3 or 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

165

166 Results

167 *Reasons for testing*

The main reason for testing over time was having symptoms, except in the first RDT study that only included asymptomatic close contacts (Table 1, Figure 2). In the PHS Amsterdam dataset, the overall percentage of test requests due to symptoms was 70.2% over the entire time period, but declined from a daily percentage between 73-97% in the period prior to 1 December 2020 to 60% on 31 May 2021; the overall percentage in the second RDT study that took place in the second quarter of 2021 was 45.2%. Having received a DCT notification, or having been contacted by the MCT programme, were minor reasons for testing in all three datasets over time. The percentages of test requests that

- 175 listed DCT as one of the reasons was 1.5% in the PHS Amsterdam dataset, 2.4% in the second RDT
- 176 study, and 7.1% in the first RDT study in asymptomatic close contacts. These percentages were 4.9%,
- 177 1.9%, and 12.3% for MCT, respectively. Direct notification by a housemate who tested positive or
- 178 another index case (any other person who tested positive) was much more common than DCT and
- 179 MCT notifications: 30% and 58.3% in the second and first RDT studies, respectively. In the first RDT
- 180 study among asymptomatic close contacts, direct notification by index cases was consistently the
- 181 main reason for testing over time.

182 Table 1: Reasons for testing in the PHS Amsterdam, first RDT, and second RDT studies in the

183 Netherlands, 2020-2021

184

| | DUC American | Suct DDT | Coccerd DDT |
|---|-----------------------------------|--------------------------------|------------------------------------|
| Reasons for testing overall ¹ | PHS Amsterdam | | Second RDI |
| | n (% of total) | n (% of total) | n (% of total) |
| Study period | 01/12/20 - 31/05/21 | 14/12/20 - 06/02/21 | 12/04/21 - 14/06/21 |
| Symptoms only | 394,408 (70.2) | NA | 3,586 (45.2) |
| Close contact ² | 35,744 (6.4) | 3,688 (89.3) | 3,682 (46.5) |
| Other reason ³ | NA | NA | 259 (3.3) |
| Multiple reasons reported, including close contact ⁴ | NA | NA | 48 (0.6) |
| Multiple reasons reported, not including close contact ⁵ | NA | NA | 56 (0.7) |
| Unknown ⁶ | 132,007 (23.5) | 443 (10.7) | 294 (3.7) |
| Total | 562,159 | 4,131 | 7,925 |
| Reasons for testing by type of | | n 1% of total % of subtots | 50 |
| close contact | | | ar j |
| DCT notification | 5,016 (0.9, 14.0) | 228 (5.5, 6.2) | 138 (1.7, 3.7) |
| MCT notification | 18,894 (3.4, 52.9) | 307 (7.4, 8.3) | 40 (0.5, 1.1) |
| Index notification | NA | 2,388 (57.8, 64.8) | 1,495 (18.9, 40.1) |
| Housemate tested positive | NA | NA | 414 (5.2, 11.1) |
| Self-referral (own initiative) ² | NA | 479 (11.6, 13.0) | 240 (3.0, 6.4) |
| Combinations incl housemate ⁷ | NA | NA | 466 (5.9, 12.5) |
| Combinations inc DCT, not housemate ⁸ | 3,215 (0.6, 9.0) | 65 (1.6, 1.8) | 54 (0.7, 1.4) |
| Combinations inc MCT, not housemate or DCT ⁹ | 8,619 (1.5, 24.1) | 200 (4.8, 5.4) | 112 (1.4, 3.0) |
| Other combinations ¹⁰ | NA | 21 (0.5, 0.6) | 0 |
| Unknown type of notification ¹¹ | NA | NA | 771 (9.7, 20.7) |
| Subtotal | 35,744 | 3,688 | 3,730 |
| | | n (% of total, % of subtota | al) |
| DCT alone or with other reasons | 8,231 (1.5, 23.0) | 293 (7.1 <i>,</i> 7.9) | 192 (2.4, 5.1) |
| MCT alone or with other reasons | 27,932 (5.0, 78.1) | 507 (12.3, 13.7) | 152 (1.9, 4.1) |
| Abbreviations: DCT=digital contact tracing | ; (CoronaMelder notification); | GP=general practitioner; MCT=m | anual contact tracing (notificatio |

by Public Health Service staff); NA = not applicable (symptoms as a reason for testing in the first RDT study) or not assessed (all other cases); PHS=public health service; RDT=rapid diagnostic test.

1. Sample sizes are for number of tests and number of individuals in the first and second RDT study (on etest per individual), and 562, 159 tests by 372,545 individuals in the PHS Amsterdam dataset.

2. Close contact includes a DCT, MCT, index, housemate, or unknown notification, or testing at one's own initiative after someone tested positive in the person's social circle (self-referral). Includes combinations of close contact notifications.

191 192 In the second RDT study, other reason included travel-related testing after having been in an orange- or red-coded country based on 193 SARS-CoV-2 risk (n=103), advised by the GP (n=75), or a different reason (n=81). The different reasons included having had a positive 194 self-test (n=10), work/school/event asked for a test (n=18), testing after 5-days of quarantine (n=4), precautionary testing (e.g. before 195 visiting an elderly relative) (n=43), and interested in finding out whether still positive (n=6). 196

4. In the second RDT study: close contact + GP (n= 37), close contact + travel (n=7), close contact + GP + travel (n=4).

197 5 In the second RDT study: symptoms + travel (n=6), symptoms + GP (n=50).

198 6. Data were not available: either the data were not recorded by contact tracing staff in the PHS Amsterdam dataset, or the question was 199 not answered by the RDT participants.

200 In second RDT study: housemate + DCT (n=18), housemate + MCT (n=53), housemate + index (n=288), housemate + DCT + MCT (n=8), 201 housemate + DCT + index (n=17), housemate + MCT+ index (n=69), housemate + DCT + MCT + index (n=13).

202 8. In the PHS Amsterdam dataset: DCT + symptoms (n=2,769), DCT + MCT (n=275), and DCT + MCT + symptoms (n=144). In the first RDT 203 study: DCT+MCT (n=4), DCT + index (n=38), DCT + self-referral (n=3; see 2 for definition), DCT + MCT + index (n=19), and DCT + MCT + 204 index + self-referral (n=1). In second RDT study: DCT + index (n=44), DCT + MCT + index (n=10).

205 9. In the PHS Amsterdam dataset: MCT + symptoms (n=8,619). In the first RDT study: MCT + index (n=189), MCT + self-referral (n=7; see 2 206 for definition), and MCT + index + self-referral (n=4). In the second RDT study, MCT + index (n=111), MCT + self-referral (n=1). 207

10. In the first RDT study: index + self-referral (n=21; see 2 for definition).

208 11. In the second RDT study this includes individuals who indicated that they had received an exposure notification but did not specify 209 which one.

210

185 186

187

188

189

Figure 2: Reasons for testing over calendar time in the PHS Amsterdam, first RDT, and second RDT

212 datasets in the Netherlands, 2020-2021





214 215 216 217

Abbreviations: DCT=digital contact tracing; Index=a person who tested SARS-CoV-2 positive; MCT=manual contact tracing; PHS=public health service; RDT=rapid diagnostic test; Self=testing at one's own initiative.

16 In Figure 1A, the first vertical dashed line represents the launch of the CoronaMelder app and the second one the change in testing policy, allowing asymptomatic individuals to get tested after exposure to a close contact. Figure 1A is based on 908,060 tests by 560,775

218 individuals; 1B on 4, 126 tests by 4, 126 individuals; and 1C on 7, 925 tests by 7, 925 individuals.

| 219 | Most test requests in the PHS Amsterdam dataset (72.2%) and the second RDT study (62.3%) |
|-----|--|
| 220 | included symptoms as one of the reasons for testing (Tables S1A and S1C). In the first RDT study, |
| 221 | 9.2% of asymptomatic close contacts developed symptoms by the time of testing (Table S1B). |
| 222 | Furthermore, a substantial proportion of test requesters who reported a DCT or MCT notification |
| 223 | also indicated the presence of symptoms (36% or 31% in the PHS Amsterdam dataset and 20% or |
| 224 | 28% in the second RDT study, respectively). Test population characteristics (such as age and gender) |
| 225 | by reasons for testing are shown in Tables S1A-C and described in the Supplementary results. |
| 226 | |
| 227 | Test positivity percentages |
| 228 | The overall SARS-CoV-2 test positivity was roughly 9% in all datasets (Tables S1A-C). Test positivity in |
| 229 | the DCT notification groups was lower than the overall test positivity in the PHS Amsterdam dataset |
| 230 | (6.1%), first RDT study (3.4%), and second RDT study (3.7%), but this only reached statistical |
| 231 | significance in the former two studies. Test positivity was statistically significantly higher than the |
| 232 | overall test positivity in the MCT notification group of the PHS Amsterdam dataset (17.6%), and in |
| 233 | the household (22.8%) and unknown notification (13.6%) groups in the second RDT study. |
| 234 | |
| 235 | Mean exposure-testing intervals |
| 236 | In the PHS Amsterdam MCT subset, first RDT study, and second RDT study, the mean exposure- |
| 237 | testing intervals were 3.9 (SD 2.6), 4.9 (SD 1.5), and 4.3 (SD 2.0) days, respectively (Tables S2A-C). The |
| 238 | DCT notification groups had similar or slightly shorter mean exposure-testing intervals (ranging from |
| 239 | 4.2 to 5.2 days) than the MCT notification groups (ranging from 4.5-5.1 days) in all three datasets, but |
| 240 | longer intervals than the symptoms group (data available for the PHS Amsterdam MCT subset only; |
| 241 | mean 3.1 days) and the household notification group (data available for the second RDT study only; |
| 242 | mean 3.1 days). Mean exposure-testing intervals for having been notified by an index case or testing |
| 243 | at one's own initiative were in between those for symptoms or household notification on the one |
| 244 | hand and DCT or MCT notification on the other hand (Tables S2A-C). Mean exposure-testing intervals |
| | |

by other test population characteristics are shown in Tables S2A-C and described in the

246 Supplementary results.

247

248 Weibull regression models with exposure-testing interval as outcome

249 The univariable Weibull models showed that testing after having received a DCT notification was 250 associated with a statistically significantly 4-7% longer exposure-testing interval compared to all 251 other reason for testing groups in all three datasets, but this only remained significant in the 252 multivariable models of the PHS Amsterdam MCT subset and second RDT study (8% and 10%, 253 respectively; Tables 2A-C). In uni- and multivariable Weibull models, testing after MCT notification 254 was associated with a statistically significantly longer interval in the second RDT study (6% and 11%, 255 respectively), testing after index case notification with a shorter interval in the first RDT study (5% 256 and 5%, respectively), testing after a household notification with a shorter interval in the second RDT 257 study (14% and 14%, respectively), and testing at one's own initiative with a longer interval in the 258 second RDT study (9% and 11%, respectively). In the PHS Amsterdam MCT subset, individuals who 259 were registered as cases or as household contacts had shorter exposure-testing intervals than non-260 household close contacts with long or short duration of contact (Table 2A). In the multivariable 261 Weibull model excluding cases, testing after a household contact was associated with a significantly 262 shorter interval than testing after a non-household close contacts with long or short duration of 263 contact (Table 2A).

264

In the PHS Amsterdam MCT subset, testing because of symptoms was associated with statistically significantly shorter exposure-testing intervals (13-16%) in all regression models (Table 2A). In the second RDT study, intervals were not available for individuals who tested because of having symptoms. In the group who tested because of having been exposed to a positive individual, reporting symptoms was not significantly associated with a shorter interval in the univariable and/or multivariable models but trends in that direction were apparent (Table 2C).

Version 23 March 2023

| 274 | Table 04, Dec. Res (1945). Il second de la facto de la facto de la terra de seconda estre la delle DUC Assete de se BACT e la la |
|-------|--|
| 771 | Iable 2A: Results of Weibuli regression models for the interval between last exposure and testing in days – PHS Amsterdam MCL subset |
| 5 7 5 | |
| 272 | |

| | | Univariable analysis ¹ | | Multivariable analysis ¹ | | Multivariable analysis contacts ² | | | Multivariable analysis | | | | |
|-----------------------------|----------|-----------------------------------|-----------------------------|-------------------------------------|-------------------------|--|---------|-----------------------|--|---------|-----------------------|-----------|---------|
| (n _{e·t} = 20,647) | | | (n _{e-t} = 20,647) | | | (n _{e t} = 15,051) | | | asymptomatics ³ (n _{e t} = 11,992) | | | | |
| Coefficients | | ETR ⁴ | 95% CI | p-value | ETR ⁴ | 95% CI | p-value | ETR ⁴ | 95% CI | p-value | ETR⁴ | 95% CI | p-value |
| Age: | 0-14 | 1.10 | 1.08-1.12 | <0.01 | 1.07 | 1.04-1.09 | <0.01 | 1.08 | 1.06-1.10 | <0.01 | 1.06 | 1.04-1.08 | <0.01 |
| | 15-29 | reference | | | reference | | | reference | | | reference | | |
| | 30-44 | 1.02 | 1.00-1.04 | 0.04 | 1.01 | 0.99-1.03 | 0.24 | 1.05 | 1.03-1.07 | <0.01 | 1.03 | 1.01-1.05 | 0.01 |
| | 45-59 | 1.03 | 1.00-1.05 | 0.01 | 1.03 | 1.01-1.05 | <0.01 | 1.04 | 1.02-1.06 | <0.01 | 1.01 | 0.99-1.04 | 0.24 |
| | 60+ | 1.08 | 1.05-1.11 | <0.01 | 1.07 | 1.04-1.09 | <0.01 | 1.07 | 1.04-1.10 | <0.01 | 1.07 | 1.04-1.10 | <0.01 |
| Gender: | Female | reference | | | reference | | | reference | | | reference | | |
| | Male | 1.02 | 1.01-1.04 | <0.01 | 1.02 | 1.00-1.03 | <0.01 | 1.02 | 1.01-1.04 | <0.01 | 1.01 | 1.00-1.03 | 0.07 |
| Municipality | /: | | | | | | | | | | | | |
| Amsterdan | n | reference | | | reference | | | reference | | | reference | | |
| Surroundir | Ig | 0.99 | 0.97-1.00 | 0.12 | 0.98 | 0.96-0.99 | <0.01 | 0.97 | 0.96-0.99 | <0.01 | 0.99 | 0.97-1.00 | 0.21 |
| Type of cont | :act:⁵ | | | | | | | | | | | | |
| Household | | reference | | | reference | | | reference | | | reference | | |
| Close, long | , | 1.07 | 1.05-1.09 | <0.01 | 1.07 | 1.06-1.09 | <0.01 | 1.06 | 1.04-1.08 | <0.01 | 1.01 | 1.00-1.03 | 0.10 |
| Close, shor | t | 1.09 | 1.02-1.17 | <0.01 | 1.10 | 1.03-1.17 | <0.01 | 1.08 | 1.02-1.14 | 0.01 | 1.06 | 0.99-1.13 | 0.09 |
| Other cont | act | 1.00 | 0.86-1.17 | 0.99 | 1.00 | 0.85-1.16 | 0.98 | 0.98 | 0.85-1.13 | 0.77 | 1.01 | 0.86-1.20 | 0.88 |
| Case | | 0.87 | 0.86-0.89 | <0.01 | 0.91 | 0.89-0.92 | <0.01 | Not incl | | | 0.88 | 0.87-0.90 | <0.01 |
| DCT: | No | reference | | | reference | | | reference | | | reference | | |
| | Yes | 1.06 | 1.00-1.12 | 0.05 | 1.08 | 1.01-1.14 | 0.02 | 1.09 | 1.02-1.16 | <0.01 | 1.10 | 1.03-1.18 | <0.01 |
| Symptoms: | No | reference | | | reference | | | reference | | | Not | | |
| | Yes | 0.84 | 0.83-0.85 | <0.01 | 0.86 | 0.85-0.88 | <0.01 | 0.87 | 0.85-0.88 | <0.01 | included | | |
| Test result: | Negative | reference | | | Not | | | Not | | | Not | | |
| | Positive | 0.89 | 0.88-0.91 | <0.01 | included ⁶ | | | included ⁶ | | | included ⁶ | | |

Abbreviations: CI = confidence interval; DCT=digital contact tracing; ETR=event-time ratio; Index=a person who tested SARS-CoV-2 positive; MCT=manual contact tracing; PHS=public health service; RDT=rapid diagnostic test; Self=testing at one's own initiative.

1. Based on 20,647 exposure- testing intervals (ne,-) by 20,355 individuals (n;) between 1 December 2020- 31 March 2021. Missing values for type of contact (ne,-= 69), test result (ne,-= 78), and gender (ne,-= 47).

2. Based on 15,051 exposure-test intervals (ne.) in 14,827 individuals (n). Missing values for type of contact (ne.) = 69), test result (ne.) = 60) and gender (ne.) = 27).

3. Based on 11,992 exposure-test intervals (ne.,) in 11,855 asymptomatic individuals (ni). Missing values for type of contact (ne.t=40), test result (ne.t=47) and gender (ne.t=28).

4. The outcome measure is event time ratio (ETR). An ETR of 1.08 for having received a DCT notification can be interpreted as the relative increase in the time interval between exposure and testing by approximately 8 percent as compared to not having received a DCT notification.

5. "Close" is defined as within 1.5 meters of an infectious person; "long" as more than 15 minutes; "short" as 15 minutes or less but with high intensity (e.g. coughing in someone's face, kissing); "household" as a close contact within the same residence; and "other" as any other contact with an infectious person. 283

6. Test result was highly correlated with contact type and was therefore not included in the multivariable models.

284

medRxiv preprint doi: https://doi.org/10.1101/2023.04.27.23289149; this version posted May 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

| | | Univaria | able analysis ¹ (n= | 3,646) | Multivariable analysis ¹ (n= 3,646) | | | | |
|-----------------|-----------|------------------|--------------------------------|---------|--|-----------|---------|--|--|
| Coefficients | | ETR ² | 95% CI | p-value | ETR ² | 95% CI | p-value | | |
| Age: | 16-29 | reference | | | reference | | | | |
| | 30-44 | 1.02 | 1.00-1.04 | 0.13 | 1.02 | 1.00-1.04 | 0.11 | | |
| | 45-59 | 1.00 | 0.98-1.02 | 0.95 | 0.99 | 0.97-1.01 | 0.58 | | |
| | 60+ | 1.03 | 1.01-1.06 | <0.01 | 1.02 | 1.00-1.05 | 0.04 | | |
| Gender: | Female | reference | | | reference | | | | |
| | Male | 1.00 | 0.98-1.02 | 0.97 | 1.00 | 0.98-1.01 | 0.92 | | |
| Testing region: | Brabant | reference | | | reference | | | | |
| | Rotterdam | 0.96 | 0.94-0.97 | <0.01 | 0.97 | 0.95-0.98 | <0.01 | | |
| DCT: | No | reference | | | reference | | | | |
| | Yes | 1.04 | 1.01-1.07 | <0.01 | 1.00 | 0.96-1.04 | 0.96 | | |
| MCT: | No | reference | | | reference | | | | |
| | Yes | 1.02 | 1.00-1.05 | 0.05 | 1.00 | 0.97-1.02 | 0.76 | | |
| Index: | No | reference | | | reference | | | | |
| | Yes | 0.95 | 0.94-0.97 | <0.01 | 0.95 | 0.92-0.98 | <0.01 | | |
| Self: | No | reference | | | reference | | | | |
| | Yes | 1.02 | 1.00-1.04 | 0.12 | 0.97 | 0.94-1.01 | 0.16 | | |
| Unknown | No | reference | | | reference | | | | |
| Contact: | Yes | 1.00 | 0.92-1.11 | 0.86 | 0.97 | 0.87-1.07 | 0.51 | | |
| Symptoms: | No | reference | | | reference | | | | |
| | Yes | 1.02 | 0.99-1.05 | 0.14 | 1.03 | 1.00-1.06 | 0.03 | | |
| Test result: | Negative | reference | | | reference | | | | |
| | Positive | 0.98 | 0.96-1.01 | 0.25 | 0.98 | 0.96-1.01 | 0.25 | | |

Table 2B: Results of Weibull regression models for the interval between last exposure and testing in days – first RDT study

287 288

289 290

291

292

293

294

Abbreviations: Cl=confidence interval; DCT=digital contact tracing; ETR=event-time ratio; Index=a person who tested SARS-CoV-2 positive; MCT=manual contact tracing; PHS=public health service; RDT=rapid diagnostic test; Self=testing at one's own initiative.

 Includes 3, 646 exposure-test intervals in 3, 646 participants between 14 December 2020 - 6 February 2021. Only participants who reported a close contact were asked the date of last exposure and dates are missing (n=480) or not logical (before testing date or more than 14 days after testing, n=5). Additional missing values for symptoms (n=21), age (n=9), gender (n=14), and test location (n=9).

2. The outcome measure is event time ratio (ETR). An ETR of 1.04 for having received a DCT notification can be interpreted as the relative increase in the time interval between exposure and testing by approximately 4 percent as compared to not having received a DCT notification.

| | | Univariable analysis ¹ (n=3.172) Multivariable analysis ¹ (n=3.172) | | | | | | Multivariable among asymptomatic ² $(n=2.179)$ | | | | | |
|-----------------|-----------|---|-------------|---------|------------------|-------------|---------|---|------------|---------|--|--|--|
| Coefficients | | ETR ³ | 95% CI | p-value | ETR ³ | 95% CI | p-value | ETR ³ | 95% CI | p-value | | | |
| Age: | 16-29 | reference | | | reference | | | reference | | | | | |
| Ů | 30-44 | 1.03 | 1.00-1.06 | 0.08 | 1.01 | 0.98- 1.04 | 0.69 | 1.00 | 0.96-1.03 | 0.92 | | | |
| | 45-59 | 1.01 | 0.97-1.04 | 0.73 | 1.01 | 0.97- 1.04 | 0.70 | 0.99 | 0.96-1.03 | 0.76 | | | |
| | 60+ | 1.03 | 0.98-1.08 | 0.20 | 0.98 | 0.93- 1.02 | 0.32 | 0.95 | 0.90- 1.00 | 0.07 | | | |
| Gender: | Female | reference | | | reference | | | reference | | | | | |
| | Male | 0.99 | 0.96-1.01 | 0.35 | 0.99 | 0.97-1.02 | 0.49 | 0.99 | 0.96-1.02 | 0.38 | | | |
| Testing region: | Brabant | reference | | | reference | | | reference | | | | | |
| | Rotterdam | 0.99 | 0.96-1.02 | 0.62 | 0.99 | 0.96- 1.02 | 0.68 | 0.98 | 0.95-1.01 | 0.23 | | | |
| | Zwolle | 0.96 | 0.93 - 1.00 | 0.03 | 0.95 | 0.91-0.98 | <0.01 | 0.97 | 0.93-1.00 | 0.07 | | | |
| DCT: | No | reference | | | reference | | | reference | | | | | |
| | Yes | 1.07 | 1.02-1.13 | <0.01 | 1.10 | 1.04 - 1.16 | <0.01 | 1.05 | 0.99-1.11 | 0.08 | | | |
| MCT: | No | reference | | | reference | | | reference | | | | | |
| | Yes | 1.06 | 1.01-1.10 | 0.02 | 1.11 | 1.06 -1.16 | <0.01 | 1.08 | 1.03-1.13 | <0.01 | | | |
| Index: | No | reference | | | reference | | | reference | | | | | |
| | Yes | 1.03 | 1.00-1.05 | 0.04 | 1.04 | 0.99- 1.08 | 0.10 | 1.02 | 0.98- 1.07 | 0.30 | | | |
| Housemate: | No | reference | | | reference | | | reference | | | | | |
| | Yes | 0.86 | 0.84-0.89 | <0.01 | 0.86 | 0.83- 0.90 | <0.01 | 0.92 | 0.88- 0.95 | <0.01 | | | |
| Self: | No | reference | | | reference | | | reference | | | | | |
| | Yes | 1.09 | 1.03-1.16 | <0.01 | 1.11 | 1.03 -1.19 | <0.01 | 1.12 | 1.03-1.21 | <0.01 | | | |
| Unknown | No | reference | | | reference | | | reference | | | | | |
| Contact: | Yes | 1.02 | 0.98-1.05 | 0.29 | 1.03 | 0.97- 1.08 | 0.34 | 1.05 | 0.99- 1.11 | 0.08 | | | |
| Symptoms: | No | reference | | | reference | | | Not included | | | | | |
| | Yes | 0.98 | 0.95-1.00 | 0.08 | 0.98 | 0.95- 1.01 | 0.22 | Not included | | | | | |
| Test result: | Negative | reference | | | reference | | | reference | | | | | |
| | Positive | 0.93 | 0.89-0.96 | <0.01 | 0.95 | 0.92- 0.99 | 0.02 | 0.92 | 0.87-0.97 | <0.01 | | | |
| Vaccinated: | No | reference | | | reference | | | reference | | | | | |
| | Yes | 1.04 | 1.00-1.08 | 0.07 | 1.03 | 0.99- 1.08 | 0.16 | 1.04 | 0.99- 1.09 | 0.09 | | | |
| Previous | No | reference | | | reference | | | reference | | | | | |
| infection: | Yes | 1.00 | 0.96-1.04 | 0.95 | 1.00 | 0.95- 1.04 | 0.84 | 0.98 | 0.94- 1.03 | 0.37 | | | |

Table 2C: Results of Weibull regression models for the interval between last exposure and testing in days – second RDT study

297 298 Abbreviations: CI=confidence interval; DCT=digital contact tracing; ETR=event-time ratio; index=a person who tested SARS-CoV-2 positive; MCT=manual contact tracing; PHS=public health service; RDT=rapid diagnostic test; Self=testing at one's own initiative. 299

1. Includes 3,172 exposure-test intervals in 3,172 participants between 12 April- 14 June 2021. Only participants who reported a close contact were asked the date of last exposure and dates are missing (n=5 19) or not

logical (before testing date or more than 14 days after testing, n=39). Additional missing values for symptoms (n=13), age (n= 6), gender (n=9), vaccination status (n=1), and prior SARS-CoV-2 infection (n= 9).

2,179 exposure test intervals in 2,179 participants. Missing values for age (n=4), gender (n=7), and prior SARS-CoV-2 infection (n=3). 2.

| | | L/L/D Chipobalic testime. | c. raio ב, ב, o pai. | in or painton in it oo ing ita | | , ,, aa. pe | | | | | |
|-----|----|---------------------------|----------------------|--------------------------------|------------------------------|--------------|-------------------------------------|-------------------|-----------------------|-------------------|-------------------------|
| 302 | 3. | The outcome measure | is event time ratio | (ETR). An ETR of 1. | 04 for having received a DCT | notification | n can be interpreted as the relativ | e increase in the | time interval between | exposure and test | ting by approximately 4 |
| 303 | | percent | as | compared | to | not | having | received | а | DCT | notification. |

Version 23 March 2023

300

301

| 304 | In the PHS Amsterdam MCT subset, individuals who ended up testing positive had a 11% shorter |
|-----|---|
| 305 | exposure-test interval than those who ended up testing negative (Table 2A). Similar trends were seen |
| 306 | in the first and second RDT study (Tables 2B-C), but only reaching significance in the second RDT |
| 307 | study (7% shorter in univariable and 5% shorter in the multivariable models). In the second RDT |
| 308 | study, COVID-19 vaccination status and previous SARS-CoV-2 infection were not significantly |
| 309 | associated with exposure-testing intervals (Table 2C). The tobit censored regression model results |
| 310 | are shown in Tables S3A-C and described in the Supplementary results. |
| 311 | |
| 312 | Discussion |
| 313 | We found that the epidemiological impact of both DCT and MCT were limited during the Dutch 2020- |
| 314 | 2022 SARS-CoV-2 epidemic. Only around 2% of all tests took place after a DCT notification, and 2-5% |
| 315 | after a MCT notification depending on MCT capacity at the time. Additionally, test positivity among |
| 316 | those testing after a DCT notification was significantly lower than among individuals testing for other |
| 317 | reasons, the exposure-test intervals were longer after a DCT or MCT notification than for other |
| 318 | reasons for testing, and about 20-36% of those who had received a DCT or MCT notification had |
| 319 | symptoms at the time of test request and might have tested anyway even without having received |
| 320 | the notification. These findings are in line with a self-evaluation performed by the Dutch PHS (GGD- |
| 321 | GHOR) that found that the majority of tests at PHS test sites were not triggered by MCT or DCT |
| 322 | notification, and test positivity was lower than average after DCT notification (13). |
| 323 | |
| 324 | By the end of May 2021, almost 30% of the Dutch population had downloaded the CoronaMelder |
| | |

325 app but only around 18% were still actively using it (5). These percentages were similar to those in

- other countries that rolled out voluntary DCT: DCT apps were downloaded by 28% of the Norwegian
- 327 population (14), 28% of the UK population (15), 26% of the Swiss population (declining to 22% active
- 328 users over time) (16), 17% of the Canadian population (17), and use was reported by 21% of cases in
- 329 Finland and 22% of cases in New South Wales, Australia (18). Direct comparisons between

Version 23 March 2023

330 epidemiological impact study results in these countries are not possible because of differences in 331 how the contact-tracing apps were embedded within existing public health infrastructures, 332 availability of data, and the degree of empirical evidence versus mathematical modelling used to 333 estimate impact. However, overall, they showed only modest (14,15,19) to limited impact (5,18,20-334 22), with results being least pronounced when conclusions were predominantly based on empirical 335 evidence. 336 337 Most impact studies cited low uptake as the main reason for the limited DCT impact, and several 338 barriers to adoption have been identified: concerns about cybersecurity and privacy; lower levels of 339 education, income, expectation about efficacy/perceived benefits, self-efficacy, and trust in 340 government; higher age; and living in a community with lower levels of use (5,23–28). Several of these 341 barriers are amenable to intervention, such as education and promotion campaigns. These campaigns 342 were suboptimal in the Netherlands (5). In addition, combining DCT apps with other practical 343 functionalities might have improved uptake. For example, the UK National Health Service (NHS) 344 COVID-19 app included multiple functionalities and fared better than CoronaMelder: it was still 345 regularly being used by around 28% of the British population by the end of December 2021 (15). These 346 functionalities included a symptom checker connected to test requesting, a QR-scanner for checking 347 into certain venues, and current government SARS-CoV-2 prevention guidelines in the local area. The 348 Dutch government considered combining the functionalities of the CoronaMelder and CoronaCheck 349 apps (to generate vaccination, test, and/or cure certificates) into one app, as has been done by other

European governments such as Germany (Corona-Warn-App), Austria (The Stopp Corona App), and France (TousAntiCovid) (20,29), but eventually decided against this. This may have been a missed opportunity. The CoronaCheck app had been downloaded by 90% of the Dutch population by 1 March

353 2022 (30).

354

355 Our analyses suggest that the PHS MCT programme did not contribute much to epidemic control

Version 23 March 2023

| 356 | either. Unfortunately, we could not compare these findings to the above-mentioned impact studies |
|-----|---|
| 357 | because those studies did not place DCT in the wider context of other reasons for testing. In our |
| 358 | study, most people in all three datasets tested because of having symptoms or because they |
| 359 | themselves found out that someone in their social circle had tested positive. While MCT will likely |
| 360 | continue to play an important role in the control of infectious diseases, its utility in the context of |
| 361 | respiratory viruses that rapidly transmit within general populations should be re-evaluated. For |
| 362 | example, instead of trying to maintain MCT at population level after containment has failed (which |
| 363 | was regularly the case in the 2020-2022 Dutch SARS-CoV-2 epidemic), more focussed uses might be |
| 364 | more appropriate and cheaper. |
| 365 | |
| 366 | Unexpectedly, we found that DCT and MCT did not shorten delays between last exposure and testing |
| 367 | compared to symptom-based testing. We hypothesise that suboptimal testing policies and |
| 368 | CoronaMelder procedures are partly to blame for this. Between 1 December 2020 and 18 February |
| 369 | 2022, exposed but asymptomatic individuals were advised to test five days after exposure, hence the |
| 370 | fairly uniform distribution of 5-day intervals in the first RDT study. Furthermore, when a |
| 371 | CoronaMelder user tested positive, they had to wait for a PHS employee to contact them to be able |
| 372 | to notify their contacts. A Swiss study reported that non-household MCT contacts who had also |
| 373 | received a SwissCovid app notification generally went into quarantine a day earlier than non- |
| 374 | household MCT contacts who had not received one (31). Nevertheless, the Swiss team also identified |
| 375 | unnecessary delays due to several bottlenecks in the exposure-notification-action cascade, such as |
| 376 | delayed delivery of codes for test result sharing, complex user interfaces, and misaligned incentives |
| 377 | for subsequent mitigation behaviours (16). |
| 378 | |
| 379 | The main limitations of our study relate to data availability and quality. To safeguard privacy, the only |

380 publicly accessible CoronaMelder-generated data are anonymous data on app downloads and active

use (the number of smartphones connecting with the backend server) (5). We therefore had to use

| 382 | proxy data sources. First, all three datasets that we used consisted mostly of self-reported data, |
|-----|--|
| 383 | which can suffer from misreporting and/or recall bias. For example, the last exposure date was not |
| 384 | always available. Individuals who booked a test online had to consistently answer questions about |
| 385 | CoronaMelder use to be able to make a booking, but these questions were less consistently asked |
| 386 | and recorded when individuals booked a test by phone or within the MCT process (32). Second, test |
| 387 | policies evolved over time. We already mentioned the day-5 test policy for individuals without |
| 388 | symptoms. In addition, from 31 March 2021 onwards, self-testing became increasingly available and |
| 389 | popular. The effects of this on our analyses are, however, limited because the three studies included |
| 390 | in this report ran until mid-June 2021, before self-testing really took off. Third, we relied heavily on |
| 391 | HPZone data for some of the PHS Amsterdam analyses, which limited the study population to |
| 392 | individuals who had participated in the MCT programme. Furthermore, MCT capacity and guidelines |
| 393 | fluctuated over time. Finally, we attempted to control for confounding in the multivariable models, |
| 394 | but residual confounding cannot be excluded. |
| 395 | |
| 396 | We conclude that both DCT and MCT had limited impacts on the Dutch 2020-2022 SARS-CoV-2 |
| 397 | epidemic. However, in future epidemics, the impact of DCT might be improved by concerted efforts |
| 398 | to increase app use coverage, elimination of contact-tracers from the digital notification process to |

399 minimise delays, and ensuring that everyone who is notified can get tested right away, including by

400 self-testing.

Acknowledgments

We thank our colleagues at the various Public Health Services and associated laboratories, the Julius Center for Health Sciences and Primary Care at the University Medical Center Utrecht, the National Institute for Public Health and the Environment (RIVM), and the Erasmus University Medical Center who contributed to the studies described in this paper.

Author contributions

JHHMvdW, AM, and JB initiated and designed the study. WTH assembled and analysed the data with input from JB, AM, and JHHMvdW. ES, RV, SvdH, JK, CM, and JHHMvdW designed the questionnaires of the first and second RDT studies and implemented those studies. WTH and JHHMvdW wrote the first draft of this manuscript and all other authors critically read the manuscript and provided feedback.

Funding

The first and second RDT studies were funded by the Dutch Ministry of Health, Welfare, and Sport. The funder had no role in study design; data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests

JHHMvdW, JK, and CM were members of the Dutch Ministry of Health, Welfare, and Sport advisory committee on digital support of SARS-CoV-2 control. WE was a member of the Dutch Ministry of Health, Welfare, and Sport task force on digital support of SARS-CoV-2 control, and was commissioned by the Dutch Ministry of Health, Welfare and Sport to evaluate CoronaMelder.

Data availability

PHS Amsterdam data are not publicly available for privacy reasons. Individual participant data of the two RDT studies will be made available, after deidentification, to researchers who provide a methodologically sound proposal. Proposals should be directed to Professor Carl Moons (k.g.m.moons@umcutrecht.nl). Data requestors will need to sign a data access agreement.

References

- 1. Braithwaite I, Callender T, Bullock M, Aldridge RW. Automated and partly automated contact tracing: a systematic review to inform the control of COVID-19. Lancet Digit Health. 2020 Nov 1;2(11):e607–21.
- Jenniskens K, Bootsma MCJ, Damen JAAG, Oerbekke MS, Vernooij RWM, Spijker R, et al. Effectiveness of contact tracing apps for SARS-CoV-2: A rapid systematic review. BMJ Open. 2021 Jul 12;11(7):e050519.
- 3. Nebeker C, Kareem D, Yong A, Kunowski R, Malekinejad M, Aronoff-Spencer E. Digital exposure notification tools: A global landscape analysis. medRxiv. 2022 Jan 1;2022.06.02.22275925.
- 4. Kretzschmar MEE, Bruijning-Verhagen P, Bootsma MCJ, Bonten MJM, van de Wijgert JHHM. Digitale middelen in de strijd tegen COVID-19. Ned Tijdschr Geneeskd. 2020 Aug 14;164:D5280.
- Ebbers W, Hooft L, van der Laan LN, Metting E. Evaluatie CoronaMelder: een overzicht na 9 maanden [Internet]. Ministerie van Volksgezondheid, Welzijn en Sport; 2021 [cited 2023 Feb 5]. Available from: https://www.rijksoverheid.nl/documenten/publicaties/2021/05/28/rapportenevaluatie-coronamelder-9-maanden
- 6. Oliver N, Lepri B, Sterly H, Lambiotte R, Deletaille S, De Nadai M, et al. Mobile phone data for informing public health actions across the COVID-19 pandemic life cycle. Sci Adv. 2020 Jun;6(23):eabc0764.
- Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science [Internet]. 2020 May 8 [cited 2021 Jun 14];368(6491). Available from: https://science.sciencemag.org/content/368/6491/eabb6936
- 8. Kretzschmar ME, Rozhnova G, Bootsma MCJ, Boven M van, van de Wijgert JHHM, Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. Lancet Public Health. 2020 Aug 1;5(8):e452–9.
- 9. Bradshaw WJ, Alley EC, Huggins JH, Lloyd AL, Esvelt KM. Bidirectional contact tracing could dramatically improve COVID-19 control. Nat Commun. 2021 Jan 11;12(1):232.
- 10. Kojaku S, Hébert-Dufresne L, Mones E, Lehmann S, Ahn YY. The effectiveness of backward contact tracing in networks. Nat Phys. 2021 May;17(5):652–8.
- 11. Schuit E, Veldhuijzen IK, Venekamp RP, Bijllaardt W van den, Pas SD, Lodder EB, et al. Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. BMJ. 2021 Jul 27;374:n1676.
- 12. Venekamp RP, Veldhuijzen IK, Moons KGM, van den Bijllaardt W, Pas SD, Lodder EB, et al. Detection of SARS-CoV-2 infection in the general population by three prevailing rapid antigen tests: cross-sectional diagnostic accuracy study. BMC Med. 2022 Feb 24;20(1):97.
- Dolman TL. Tabellenrapport CoronaMelder GGD GHOR Nederland [Internet]. GGD GHOR Nederland; 2021 [cited 2023 Mar 9]. Available from: https://www.rijksoverheid.nl/documenten/publicaties/2021/05/28/rapporten-evaluatiecoronamelder-9-maanden

- 14. Elmokashfi A, Sundnes J, Kvalbein A, Naumova V, Reinemo SA, Florvaag PM, et al. Nationwide rollout reveals efficacy of epidemic control through digital contact tracing. Nat Commun. 2021 Oct 11;12(1):5918.
- 15. Wymant C, Ferretti L, Tsallis D, Charalambides M, Abeler-Dörner L, Bonsall D, et al. The epidemiological impact of the NHS COVID-19 app. Nature. 2021 May 12;1–5.
- 16. Daniore P, Nittas V, Ballouz T, Menges D, Moser A, Höglinger M, et al. Performance of the Swiss digital contact-tracing app over various SARS-CoV-2 pandemic waves: Repeated cross-sectional analyses. JMIR Public Health Surveill. 2022 Nov 11;8(11):e41004.
- 17. Sun S, Shaw M, Moodie EEM, Ruths D. The epidemiological impact of the Canadian COVID Alert app. Can J Public Health Rev Can Sante Publique. 2022 Aug;113(4):519–27.
- 18. Vogt F, Haire B, Selvey L, Katelaris AL, Kaldor J. Effectiveness evaluation of digital contact tracing for COVID-19 in New South Wales, Australia. Lancet Public Health. 2022 Mar 1;7(3):e250–8.
- 19. Menges D, Aschmann HE, Moser A, Althaus CL, von Wyl V. A data-driven simulation of the exposure notification cascade for digital contact tracing of SARS-CoV-2 in Zurich, Switzerland. JAMA Netw Open. 2021 Apr 1;4(4):e218184.
- 20. Ussai S, Pistis M, Missoni E, Formenti B, Armocida B, Pedrazzi T, et al. 'Immuni' and the national health system: Lessons learnt from the COVID-19 digital contact tracing in Italy. Int J Environ Res Public Health. 2022 Jun 20;19(12).
- 21. Rannikko J, Tamminen P, Hellsten R, Nuorti JP, Syrjänen J. Effectiveness of COVID-19 digital proximity tracing app in Finland. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022 Jun;28(6):903–4.
- 22. Klinkenberg D, Leung KY, Wallinga J. CoronaMelder: modelstudie naar effectiviteit Digitaal contactonderzoek in de bestrijding van COVID-19 [Internet]. RIVM-briefrapport 2021-0092: Ministerie van Volksgezondheid, Welzijn en Sport; 2021 [cited 2023 Mar 9]. Available from: https://www.rijksoverheid.nl/documenten/publicaties/2021/05/28/rapporten-evaluatiecoronamelder-9-maanden
- 23. Ritsema F, Bosdriesz JR, Leenstra T, Petrignani MWF, Coyer L, Schreijer AJM, et al. Factors associated with using the COVID-19 mobile contact-tracing app among individuals diagnosed with SARS-CoV-2 in Amsterdam, the Netherlands: Observational study. JMIR MHealth UHealth. 2022 Aug 24;10(8):e31099.
- 24. Altmann S, Milsom L, Zillessen H, Blasone R, Gerdon F, Bach R, et al. Acceptability of app-based contact tracing for COVID-19: Cross-country survey study. JMIR MHealth UHealth. 2020 Aug 28;8(8):e19857.
- 25. Blom AG, Wenz A, Cornesse C, Rettig T, Fikel M, Friedel S, et al. Barriers to the large-scale adoption of a COVID-19 contact tracing app in Germany: Survey study. J Med Internet Res. 2021 Mar 2;23(3):e23362.
- 26. Walrave M, Waeterloos C, Ponnet K. Adoption of a contact tracing app for containing COVID-19: A Health Belief Model approach. JMIR Public Health Surveill. 2020 Sep 1;6(3):e20572.

- 27. Jansen-Kosterink S, Hurmuz M, den Ouden M, van Velsen L. Predictors to use mobile apps for monitoring COVID-19 symptoms and contact tracing: Survey among Dutch citizens. JMIR Form Res. 2021 Dec 20;5(12):e28416.
- 28. Waal NE van der, Wit J de, Bol N, Ebbers W, Hooft L, Metting E, et al. Predictors of contact tracing app adoption: Integrating the UTAUT, HBM and contextual factors. Technol Soc. 2022;71:102101.
- 29. Prodan A, Birov S, von Wyl V, Ebbers W. Covid-19 digital contact tracing study | Shaping Europe's digital future. Brussels. [Internet]. European Commission; 2022 [cited 2023 Mar 9]. Available from: https://digital-strategy.ec.europa.eu/en/library/covid-19-digital-contact-tracing-study?pk_source=ec_newsroom&pk_medium=email&pk_campaign=dae%20Newsroom
- 30. Ministry of Health, Welfare, and Sports. Aantal downloads CoronaCheck-app en -Scanner [Internet]. CoronaCheck. [cited 2023 Feb 5]. Available from: https://coronacheck.nl/nl/faq/7-13actuele-downloadcijfers/#7
- 31. Ballouz T, Menges D, Aschmann HE, Domenghino A, Fehr JS, Puhan MA, et al. Adherence and association of digital proximity tracing app notifications with earlier time to quarantine: Results from the Zurich SARS-CoV-2 Cohort Study. Int J Public Health. 2021;66:1603992.
- 32. Bente BE, van 't Klooster JWJR, Schreijer MA, Berkemeier L, van Gend JE, Slijkhuis PJH, et al. The Dutch COVID-19 contact tracing app (the CoronaMelder): Usability study. JMIR Form Res. 2021 Mar 26;5(3):e27882.

Supporting information captions

Supplementary introduction

Supplementary methods

Supplementary results

Figure S1: CoronaMelder smartphone application

Figure S2: Participant flow diagram PHS Amsterdam datasets

Figure S3: Questionnaires used in the first RDT and second RDT studies (in Dutch language)

Figure S4: Participant flow diagrams first and second RDT studies

Table S1A: Test population characteristics by reason for testing – PHS Amsterdam

Table S1B: Test population characteristics by reason for testing – first RDT study (asymptomatic close contacts)

Table S1C: Test population characteristics by reason for testing – second RDT study

Table S2A: Mean (SD) interval in days between first exposure and testing – PHS Amsterdam MCT subset

Table S2B: Mean (SD) interval in days between last exposure and testing – first RDT study (asymptomatic close contacts)

Table S2C: Mean (SD) interval in days between last exposure and testing – second RDT study

Table S3A: Tobit regression model for exposure-test intervals – PHS Amsterdam MCT subset

Table S3B: Tobit regression model for the exposure-test intervals - first RDT study

Table S3C: Tobit regression model for the exposure-test intervals - second RDT study